Results 1 to 10 of about 92,707 (329)
New Deoxycholic Acid Derived Tyrosyl-DNA Phosphodiesterase 1 Inhibitors Also Inhibit Tyrosyl-DNA Phosphodiesterase 2 [PDF]
Molecules, 2021 A series of deoxycholic acid (DCA) amides containing benzyl ether groups on the steroid core were tested against the tyrosyl-DNA phosphodiesterase 1 (TDP1) and 2 (TDP2) enzymes.
Oksana V. Salomatina +9 more
doaj +2 more sources
Effect of phosphodiesterase inhibitors on platelet function [PDF]
Biochemistry and Biophysics ReportsPhosphodiesterase enzymes (PDEs) play a pivotal role in regulating platelet activity by modulating intracellular levels of cAMP and cGMP. Modulation of PDE-2, -3 and -5 activity by suitable inhibitors has been found to reduce platelet activity, and thus ...
Ravi Hochuli +7 more
doaj +2 more sources
New Avenues for Phosphodiesterase Inhibitors in Asthma [PDF]
Journal of Experimental Pharmacology, 2021 Maria Gabriella Matera,1 Josuel Ora,2 Francesco Cavalli,2 Paola Rogliani,2,3 Mario Cazzola3 1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Respiratory Diseases Unit, “Tor Vergata&rdquo ...
Matera MG +4 more
doaj +2 more sources
Phosphodiesterase-5 inhibitors: Raynaud's and beyond
Indian Journal of Rheumatology, 2017 Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak +3 more
doaj +2 more sources
Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy [PDF]
JACC: Basic to Translational Science, 2016 Molecular mechanisms of Trypanosoma cruzi (Tc)-induced Chagasic cardiomyopathy (CCM) are not well understood. The NO-cGMP-PKG1α pathway maintains cardiac homeostasis and inotropy and may be disturbed due to phosphodiesterase (PDE5)-mediated cGMP ...
Jian-jun Wen, PhD +3 more
doaj +2 more sources
Phosphodiesterase Inhibitors [PDF]
International Cardiovascular Forum Journal, 2019 Phosphodiesterases (PDEs) comprise a superfamily with 11 subfamilies. Within these families, more than 40 isoforms are expressed. Phosphodiesterase-3 inhibitors (PDE3i) are used as inotrope/vasodilators for acute heart failure (HF), and PDE5i for pulmonary hypertension and erectile dysfunction.
Rui Plácido, Mitja Lainscak
openaire +2 more sources
The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
Frontiers in Pharmacology, 2022 Phosphodiesterase-1 (PDE1) is a versatile enzyme that has surprisingly received considerable attention as a possible therapeutic target in Alzheimer’s disease (AD) because it maintains the homeostasis of 3ʹ,5ʹ-cyclic adenosine monophosphate (cAMP) and 3ʹ,
Nazir Ahmad +5 more
doaj +1 more source
Phosphodiesterase Inhibitors: Present and Future
Barcelona Respiratory Network Reviews, 2023 Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj +1 more source
Phosphodiesterase inhibitors [PDF]
British Journal of Pharmacology, 2006 Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this ...
Boswell-Smith, V, Spina, D, Page, C P
openaire +3 more sources
Applied Sciences, 2021 Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease.
Giovanni Ribaudo +2 more
doaj +1 more source